2022-12-02

Clinical Lab Products: The Future of Cervical Cancer Screening is Here

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening

The future of cervical cancer screening is here. Featured in Clinical Lab Products, Associate Director of Medical Affairs Molly Broache notes that in today’s world where patients are catching up on missed screenings, adding pressure on already-pressured labs, it’s that much more important to take advantage of instruments and assays that do more and do better. The BD Onclarity HPV Assay is a perfect example with its cutting-edge approach to HPV testing.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Smiling woman smiling while painting
STIs | Vaginitis | Brochures
Vaginitis and STIs: The right treatment begins with the right diagnosis
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Cervical Cancer | Webinars & Videos
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
A healthy and happy woman with a cellphone
Vaginitis | Brochures
BD Vaginal Panel Reimbursement and Market Access Toolkit